Directory of Stock Market Company
This site is a directory of Stock Market Company in USA and Canada. Each company page contains a description, stock quote, news and much more. You have also access to the best stock market game on the web.
Search into NYSE and TSX
by quote, company name or key word
ASTM - Aastrom Biosciences Inc
Aastrom Biosciences, Inc. (Aastrom), incorporated in March 1989, is a clinical development-stage. The Company is engaged in research and product development involving the development of patient specific cell products for use in regenerative medicine. Aastrom is developing expanded patient specific mixed cellular therapies for use in the treatment of severe, chronic ischemic","NYSE, Nasdaq, S&P, trading, US market, Asian market, Dow Jones, FTSE, DJIA, DAX, stocks, bonds, shares","Connect to the most current information on stocks and bonds on Reuters.com. What you need to know now about NYSE, Dow Jones, S&P, and Nasdaq at Reuters.com"
Aastrom Biosciences Inc News
Medgenics Moving In Record Time
Seeking Alpha - 13 hours ago
Seeking Alpha - 13 hours ago
Medgenics (MDGN) scores again. After a season of good news, the company recently told investors that in record time, the FDA approved its filing to start clinical trials using its Biopump platform technology to treat anemia in kidney dialysis patients.
Medgenics Moving In Record Time - Review - The Mumbai Times
Osiris Therapeutics (NASDAQ:OSIR) Wins Stem Cell Medicine Approval; Shares Sky ...
PT News - 15 hours ago
PT News - 15 hours ago
Osiris Therapeutics, Inc (NASDAQ:OSIR) moved up after the corporation reported that it got the world's primary approval for a stem- cell medicine, gaining clearance in Canada to vend Prochymal for a infection that can attack patients who received ...
Osiris Therapeutics (NASDAQ:OSIR) Wins World's First Stem-Cell Therapy Approval - Gaining Green
Aastrom Biosciences to Present at World Stem Cells & Regenerative Medicine ...
PharmaLive (press release) (subscription) - May 18, 2012
PharmaLive (press release) (subscription) - May 18, 2012
ANN ARBOR, Mich., May 17, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, today announced that ...
Ascendiant Capital Starts Aastrom Biosciences (ASTM) at Strong Buy; Leading ... - StreetInsider.com (subscription)
Aastrom Biosciences to Present at World Stem Cells & Regenerative Medicine ...
Review seeker (press release) - May 18, 2012
Review seeker (press release) - May 18, 2012
By Globenewswire ANN ARBOR, Mich., May 17, 2012 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, ...
Aastrom Biosciences to Present at World Stem Cells & Regenerative Medicine ...
MarketWatch (press release) - May 17, 2012
MarketWatch (press release) - May 17, 2012
ANN ARBOR, Mich., May 17, 2012 (GlobeNewswire via COMTEX) -- Aastrom Biosciences, Inc. (NASDAQ:ASTM) , the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, ...
Ascendiant Capital Markets Analysts Begin Coverage on Aastrom Biosciences (ASTM) - Movie News Guide (blog)
Wednesday's Top Upgrades (and Downgrades)
DailyFinance - May 16, 2012
DailyFinance - May 16, 2012
By Rich Smith, The Motley Fool Stocks go up, stocks go down -- and so do analysts' opinions of them. This series, brought to you by Yahoo!
Upgrades & Downgrades: Bulls Run on Dunkin'
Minyanville.com - May 16, 2012
Minyanville.com - May 16, 2012
By Justin Sharon May 16, 2012 9:30 am MINYANVILLE ORIGINAL Zeus, the Greek god of thunder, was angry yesterday, as France's freshly sworn-in president can attest to after a pitch-perfect metaphor for Europe's fiscal crisis.
Investment Analysts' New Coverage for May, 15th (ASTM, CPA, IMUC, MPAA, NCT ...
Junction Report - May 16, 2012
Junction Report - May 16, 2012
Aastrom Biosciences Inc (NASDAQ: ASTM) is now covered by analysts at Ascendiant Capital Markets. They set a “strong-buy” rating on the stock.
Osiris Therapeutics (NASDAQ:OSIR) Posts $1.3 Million Loss in First Quarter ...
PT News - May 14, 2012
PT News - May 14, 2012
Osiris Therapeutics, Inc (NASDAQ:OSIR) announced on Friday a loss of $1.3 million or $0.04 a share in the first-quarter, evaluated against a profit of $4.0 million or $0.12 a share in the similar quarter previous year.
Equities Research Analysts' Ratings Reiterations for May, 11st (AGCO, ARX ...
Junction Report - May 12, 2012
Junction Report - May 12, 2012
AGCO Corp. (NASDAQ: AGCO) had its “outperform” rating re-affirmed by analysts at Zacks. They now have a $52.00 price target on the stock.
NYSE Media Coverage Selection of the best articles found in your favorit medias